Humanization of rabbit antibodies using a universal antibody framework
US-11858981-B2 · Jan 2, 2024 · US
huTNFR1 selective antagonists
US9045535B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9045535-B2 |
| Application number | US-201313765923-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 13, 2013 |
| Priority date | Mar 19, 2007 |
| Publication date | Jun 2, 2015 |
| Grant date | Jun 2, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a ligand, which specifically binds to human tumor necrosis factor type 1 receptor (huTNFR1). The ligand includes one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in humans and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention also relates to a nucleic acid sequence encoding the ligand and to a pharmaceutical composition for the treatment of disorders related to huTNFR1.
First claim
Opening claim text (preview).
The invention claimed is: 1. A process for the production of a huTNFR1-antagonist comprising the steps of a) providing a proteinaceous construct comprising a humanized antibody or at least one fragment thereof having i) one or more amino acid sequences of human origin capable of reducing the immunogenic response of said huTNFR1-antagonist in humans, and ii) one or more amino acid sequences of non-human origin capable of selectively binding to huTNFR1 thereby completely blockin…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9045535B2 cover?
- The present invention relates to a ligand, which specifically binds to human tumor necrosis factor type 1 receptor (huTNFR1). The ligand includes one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in humans and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention also relates to a nucleic acid …
- Who is the assignee on this patent?
- Univ Stuttgart
- What technology area does this patent fall under?
- Primary CPC classification C07K16/241. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 02 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).